A Phase 2 interventional study of Fx-1006A in Transthyretin-associated Amyloidosis With Polyneuropathy, sponsored by Pfizer. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-18.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.
Among the 141 studies in Amyloidosis with a site in United States, this one is the 77th largest by enrollment of the 99 interventional ones that give a count, is one of 3 that started in 2008, is one of 30 in phase 2, and was the 12th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
GlaxoSmithKline · Sites in United States, Australia, United Kingdom
Ages 18+
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Germany, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 46 · Phase 3 31 · Phase 4 3
First in 1979; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 45 across the 99 interventional studies, 107 across the 41 observational. Of the 84 that completed or were terminated, 44 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 141 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 8 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Amyloidosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05619302Phase 3Brigham and Women's HospitalMolecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis | 2026-12-31 |
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT06097832Nexcella Inc.Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | 2026-12 |
| NCT05951816University of Tennessee Graduate School of MedicineA Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis | 2026-12 |
| NCT07196839University of Texas Southwestern Medical CenterDetermining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 141 studies in Amyloidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label, multicenter, international study designed to determine TTR stabilization as well as Fx-1006A safety and tolerability, and its effects on clinical outcomes in patients with non-V30M TTR amyloidosis.
Strong pre-clinical and clinical evidence support a daily dose of 20 mg of Fx-1006A to be the optimum dose to achieve stabilization of tetrameric TTR in ATTR-PN patients. Since disease presentation is similar between V30M and non-V30M TTR mutations associated with ATTR-PN and Fx-1006A has been shown to stabilize wild-type and V30M TTR in vitro and ex vivo, the present study is being conducted to determine the effects of Fx-1006A on TTR stabilization in ATTR-PN patients with TTR mutations other than V30M. Safety and exploratory efficacy of Fx-1006A administered once daily for 12 months will also be evaluated in this patient population.
This is an open-label, multicenter, international study designed to determine TTR stabilization as well as Fx-1006A safety and tolerability, and its effects on clinical outcomes in patients with non-V30M TTR amyloidosis. The study will be conducted in two parts. Part 1 will include a six-week dosing period during which all enrolled patients will receive oral Fx-1006A 20 mg soft gelatin capsules once daily for six weeks. At Week 6, blood samples will be collected from each patient to determine TTR stabilization. Patients who complete the Week 6 visit will continue receiving daily oral Fx-1006A 20 mg for up to a total of 12 months during Part 2 of this study. If it is determined that a patient is not stabilized at Week 6, the patient will be discontinued from the study.
During Part 2, clinical outcomes will be measured at Months 6 and 12, based on NIS, Norfolk QOL-DN, mBMI, NCS, HRDB, SF-36, Karnofsky score, and echocardiography; NT-pro-BNP and troponin I levels will be measured at Baseline, Weeks 2 and 6, and Months 3, 6, and 12.
Pharmacokinetic measurements will be made using samples collected at Baseline, Week 6, and Months 6 and 12.
Safety and tolerability will be assessed throughout the study based on vital signs, physical examinations, ECG, echocardiography, 24-hour Holter monitoring, clinical laboratory tests (hematology, serum chemistry, and urinalysis), and monitoring adverse events and concomitant medication use.
Day 1 will be defined as administration of the first dose of study drug. Clinic Visits will be conducted during Screening (Days -30 to -1) and at Baseline (Day 0), and Week 2, and Week 6, and Months 3, 6, and 12 (± 2 weeks of the scheduled date for post-Baseline visits). Monthly telephone contacts (+ 1 week of the scheduled date) will be made during months in which no investigative site visits are scheduled (Months 4, 5, 7, 8, 9, 10, and 11) for assessment of adverse events and concomitant medications. A final telephone contact to assess adverse events and concomitant medication usage will be made 30 days after the last dose of study drug.
Patients who discontinue from the study at any time following enrollment will have a final visit performed, including all safety assessments, at the time of discontinuation. Any patient discontinuing after the Month 6 visit will also have all exploratory assessments performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fx-1006A 20mg soft gelatin capsules once daily for 12 months
Drug: Fx-1006A
During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Week 6
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
Time frame: Week 6
Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Month 6 and 12
TTR tetramer was assessed using a validated immunoturbidimetric assay. The FOI is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
Time frame: Month 6, Month 12
Number of Participants With Treatment-Emergent Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 30 days after the last dose
Number of Participants With Greater Than or Equal to Grade 3 Treatment-Emergent Adverse Events
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. On the basis of intensity, grade 3 was referred as severe, grade 4 as life-threatening and grade 5 as death.
Time frame: Baseline up to 30 days after the last dose
Number of Participants With Clinically Significant Treatment-Emergent Echocardiography (ECHO) Findings
ECHO: investigator assessed test to assess cardiac function. ECHO abnormality criteria: any abnormality, valvular abnormality, pericardial effusion, abnormal regional wall motion, inferior vena cava respiratory variation, posterior (P) left ventricular (LV) wall/septal (S) thickness, right ventricular thickness, ejection fraction, ratio of early (E) diastolic transmitral flow and atrial(A) contraction velocity (E/A), ratio of 'E'to lateral/septal mitral annular velocity (e') (E/e'prime lateral, E/e'prime septal), E deceleration time (DT), isovolumic relaxation time (IVRT).
Time frame: Day 1 up to Month 12
Number of Participants With Clinically Significant Treatment-Emergent Electrocardiogram (ECG) Findings
ECG: investigator assessed test to assess cardiac function. ECG abnormality criteria: any abnormality, arrhythmia, rhythm, conduction, morphology, myocardial infarction, ST segment, T waves and abnormal U waves.
Time frame: Day 1 up to Month 12
Number of Participants With Clinically Significant Treatment-Emergent Holter Monitoring Findings
Holter monitoring recorded heart rhythm. Holter monitoring abnormality criteria: any abnormality, atrial fibrillation/flutter, atrial tachycardia, non-sustained ventricular tachycardia (VT), sustained VT and sinus pause.
Time frame: Day 1 up to Month 12
Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events
Time frame: Baseline up to Month 12
Change From Baseline in the Neuropathy Impairment Score (NIS) at Month 6, Month 12
NIS assessed cranial nerves(nerve 3,6; facial, palate and tongue weakness),muscle weakness (respiratory; neck, elbow(E), wrist(W), finger(F), hip, knee(K) flexion; shoulder, thumb abduction; brachioradialis; E, W, hip, K extension; F spread; toe, dorsal and plantar ankle flexors; toe extensors); score: 0-4, higher score=more weakness, reflexes(biceps and triceps brachii; brachioradialis; quadriceps femoris; triceps surae), index F and great toe sensation(touch pressure, pin-prick, vibration, joint position)score:0=normal,1=decreased or 2=absent. Total score=0-244, higher score=more impairment.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in the Neuropathy Impairment Score-Lower Limb (NIS-LL) at Month 6, Month 12
NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on 0 to 4 scale, higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.
Time frame: Baseline, Month 6, Month 12
Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6, Month 12
Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to less than \[\<\] 2) in Neuropathy Impairment Score- Lower Limb (NIS-LL) score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.
Time frame: Month 6, Month 12
Change From Baseline in Total Quality of Life (TQOL) Score at Month 6, Month 12
TQOL= sum of all Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) items,a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on QOL of participants with DN; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). Total TQOL score=-2 to 138;higher score=worse quality of life.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, Month 12
Norfolk QOL-DN:35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7: scored as 1=symptom present, 0=symptom absent. Item 8-35: scored on 5-point Likert scale:0=no problem, 4=severe problem(except item 32: -2=much better, 0=about same, 2=much worse).Norfolk QOL-DN summarized in 5 domains (score range): physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptom(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12);higher score=greater impairment, for each. Total score=-2 to 138 (higher score=worse QOL).
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Nerve Conduction Studies (NCS) at Month 6, Month 12
NCS: quantitative measures of peripheral nerve dysfunction consists of 5 attributes: peroneal nerve (PN) motor distal latency, PN compound muscle action potential, PN motor conduction velocity, tibial nerve distal motor latency, sural nerve sensory nerve action potential. Normal deviates (Z-score) summated into composite score (higher score=worsened nerve fiber function). Z-score is the defined position of the result in normal probability distribution with a mean of 0 and standard deviation (std) of 1 and describes how far a score is (in std) from the mean.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Heart Rate Response to Deep Breathing (HRDB) at Month 6 and Month 12
HRDB test was used to evaluate the cardio-vagal response. Participant took a series of 8 deep breaths and average heart rate difference was measured and compared to normative data. The main factor affecting HRDB is age, with older patients showing less heart rate variability. R-R (time between two consecutive R waves in the electrocardiogram) response to deep breathing was reported as the normal deviates (Z-score), the defined position of the result in normal probability distribution with a mean of 0 and standard deviation (std) of 1 and describes how far a score is (in std) from the mean.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Modified Body Mass Index (mBMI) at Month 6, Month 12
BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2). mBMI was calculated by multiplying BMI by serum albumin levels \[gram/liter (g/L)\]. mBMI was measured as kg/m\^2\*g/L. A progressive decline in mBMI indicated worsening of disease severity.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Overall Quality of Life and Individual Domains of the Short-form-36 (SF-36) at Month 6, Month 12
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health and two total scores (physical component summary \[PCS\] and mental component summary \[MCS\]. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Echocardiography (ECHO) Parameters at Month 6, Month 12
Echocardiography was used to measure interventricular septal thickness (IVST), posterior left ventricular wall thickness (PLVWT), right ventricular wall thickness (RVWT), left atrial diameter (LAD): anterior-posterior (ant-post), medio-lateral, superior-inferior (sup-inf) and left ventricular end diastolic diameter (LVED), relative LV wall thickness (RLVWT).
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Atrial Volume at Month 6, Month 12
Left atrial volume was measured by echocardiography.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular (LV) End Systolic Volume, Left Ventricle (LV) Stroke Volume at Month 6, Month 12
Cardiac MRI was done to measure left ventricular (LV) end systolic volume, left ventricle (LV) stroke volume.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Fractional Shortening at Month 6, Month 12
Fractional shortening (FS) is the fraction of any diastolic dimension that is lost in systole. Percent of FS was calculated as difference between end-diastolic dimension (EDD) and end-systolic dimension (EDS) divided by EDD.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular (LV) Ejection Fraction at Month 6, Month 12
Cardiac MRI was done to measure left ventricular ejection fraction (LVEF) which was the fraction of the end-diastolic volume (EDV) that was ejected out of left ventricle with each contraction.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular Mass (LVM) at Month 6, Month 12
LV mass was calculated from the product of the myocardial volume and specific gravity of heart muscle, estimated by echocardiography. Increased LVM was associated with cardiovascular morbidity and mortality.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Isovolumetric Relaxation Time (IVRT), Mitral Deceleration Time at Month 6, Month 12
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. IVRT is the time between the closure of the aortic valve and the opening of the mitral valve. Mitral deceleration time (MDT) was the time taken from the maximum E point wave to baseline. E wave arises due to early diastolic filling.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Aortic Annulus Diameter at Month 6, Month 12
The diameter at the base of the aortic root, the basal ring, is also called the aortic annulus diameter.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Tricuspid Peak Velocity at Month 6, Month 12
Tricuspid peak velocity was measured by echocardiography.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Tricuspid Pulmonary Artery Systolic Pressure (PASP) at Month 6, Month 12
Systolic right ventricular pressure can be estimated on echocardiography by adding right atrial pressure (RAP) to the trans-tricuspid gradient derived from the tricuspid regurgitation velocity.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Doppler Data at Month 6, Month 12
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Doppler principle was used to measure the mitral peak early (E) diastolic transmitral flow, mitral peak atrial (A) contraction velocity and annular velocities at the lateral and septal areas of the mitral annulus. s': systolic velocity during ejection, e': early diastolic mitral annular velocity, a': late diastolic mitral annular velocity.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in e:e' Lateral Ratio , Ratio of Peak Mitral Early Diastolic and Atrial Contraction Velocity (E/A Ratio) at Month 6, Month 12
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Ratio of early (E) diastolic transmitral flow velocity and atrial (A) contraction velocity (E/A) and ratio of the early (E) diastolic transmitral flow velocity to the mitral annular velocity (e') (E/e') were estimated.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Ventricular (LV) Mass/Voltage Ratio at Month 6, Month 12
LV mass was calculated from the product of the myocardial volume and specific gravity of heart muscle, estimated by echocardiography. QRS score (the sum of QRS voltages in the peripheral leads) was used as an index of "electrical" LV mass.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Left Atrial (LA) Volume Index at Month 6, Month 12
LA volume index (LAVI), was the value of LA volume divided by body surface area, to measure LA size.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) at Week 2, Week 6, Month 3, Month 6, Month 12
NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
Time frame: Baseline, Week 2, Week 6, Month 3, Month 6, Month 12
Change From Baseline in Karnofsky Performance Status Scale at Month 6, Month 12
Karnofsky performance score is used to quantify participant's general well-being and activities of daily life and participants are classified based on their functional impairment. Karnofsky performance score is 11 level score which ranges between 0 (death) to 100 (no evidence of disease). Higher score means higher ability to perform daily tasks.
Time frame: Baseline, Month 6, Month 12
Change From Baseline in Troponin I Levels at Week 2, Week 6 , Month 3, Month 6, Month 12
Troponin I is a cardiac injury biomarker. Higher concentrations of this marker in blood are associated with heart injury.
Time frame: Baseline, Week 2, Week 6 , Month 3, Month 6, Month 12
| Milestone | Tafamidis |
|---|---|
| Started | 21 |
| Completed | 20 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
| Milestone | Tafamidis |
|---|---|
| Started | 20 |
| Completed | 18 |
| Not completed | 2 |
| Withdrew: Liver transplant | 2 |
TTR tetramer was assessed using a validated immunoturbidimetric assay. The Fraction of Initial (FOI) is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
| percentage of participants | Tafamidis |
|---|---|
| Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Week 6 | 94.7 (74.0 to 99.9) |
TTR tetramer was assessed using a validated immunoturbidimetric assay. The FOI is the ratio of the measured TTR tetramer concentration after denaturation to the measured TTR tetramer concentration before denaturation. TTR tetramer stabilization is based on the difference between the on-treatment FOI and the baseline FOI expressed as a percentage of the baseline FOI.
| percentage of participants | Tafamidis |
|---|---|
| Month 6 (n= 18) | 100.0 (81.5 to 100.0) |
| Month 12 (n= 17) | 100.0 (80.5 to 100.0) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| participants | Tafamidis |
|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) | 17 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. On the basis of intensity, grade 3 was referred as severe, grade 4 as life-threatening and grade 5 as death.
| participants | Tafamidis |
|---|---|
| Number of Participants With Greater Than or Equal to Grade 3 Treatment-Emergent Adverse Events | 3 |
ECHO: investigator assessed test to assess cardiac function. ECHO abnormality criteria: any abnormality, valvular abnormality, pericardial effusion, abnormal regional wall motion, inferior vena cava respiratory variation, posterior (P) left ventricular (LV) wall/septal (S) thickness, right ventricular thickness, ejection fraction, ratio of early (E) diastolic transmitral flow and atrial(A) contraction velocity (E/A), ratio of 'E'to lateral/septal mitral annular velocity (e') (E/e'prime lateral, E/e'prime septal), E deceleration time (DT), isovolumic relaxation time (IVRT).
| participants | Tafamidis |
|---|---|
| Any ECHO abnormalities (n= 19) | 12 |
| Pericardial effusion (n= 19) | 2 |
| Valvular abnormalities- thickening (n= 5) | 3 |
| Valvular abnormalities - regurgitation (n= 9) | 2 |
| Abnormal regional wall motion (n= 11) | 2 |
| Inferior vena cava respiratory variation (n= 13) | 0 |
| LV P wall thickness >=13 millimeter (mm) (n= 3) | 2 |
| LV S thickness >=13 mm (n= 3) | 1 |
| Right ventricular thickness >=7 mm (n= 13) | 6 |
| E/A ratio >=2 (n= 16) | 3 |
| E/e'prime Lateral >15 (n= 15) | 3 |
| E/e'prime Septal >15 (n= 10) | 2 |
| Ejection fraction < 50 percent (%) (n= 17) | 2 |
| EDT <= 150 milliseconds (msec) (n= 14) | 1 |
| IVRT <=70 msec (n= 13) | 2 |
ECG: investigator assessed test to assess cardiac function. ECG abnormality criteria: any abnormality, arrhythmia, rhythm, conduction, morphology, myocardial infarction, ST segment, T waves and abnormal U waves.
| participants | Tafamidis |
|---|---|
| Any ECG abnormalities (n= 21) | 9 |
| Arrhythmia (n= 18) | 8 |
| Rhythm (n= 18) | 1 |
| Conduction (n= 8) | 2 |
| Morphology (n= 20) | 0 |
| Myocardial infarction (n= 18) | 0 |
| ST segment (n= 20) | 1 |
| T waves (n=18) | 1 |
| Abnormal U waves (n= 21) | 0 |
Holter monitoring recorded heart rhythm. Holter monitoring abnormality criteria: any abnormality, atrial fibrillation/flutter, atrial tachycardia, non-sustained ventricular tachycardia (VT), sustained VT and sinus pause.
| participants | Tafamidis |
|---|---|
| Any Holter monitoring abnormalities (n= 19) | 9 |
| Atrial fibrillation/flutter (n= 18) | 1 |
| Atrial tachycardia (n= 9) | 4 |
| Non-sustained VT <30 beats (n= 11) | 4 |
| Sustained VT >=30 beats (n= 19) | 0 |
| Sinus pause (n= 18) | 1 |
| participants | Tafamidis |
|---|---|
| Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events | 1 |
NIS assessed cranial nerves(nerve 3,6; facial, palate and tongue weakness),muscle weakness (respiratory; neck, elbow(E), wrist(W), finger(F), hip, knee(K) flexion; shoulder, thumb abduction; brachioradialis; E, W, hip, K extension; F spread; toe, dorsal and plantar ankle flexors; toe extensors); score: 0-4, higher score=more weakness, reflexes(biceps and triceps brachii; brachioradialis; quadriceps femoris; triceps surae), index F and great toe sensation(touch pressure, pin-prick, vibration, joint position)score:0=normal,1=decreased or 2=absent. Total score=0-244, higher score=more impairment.
| units on a scale | Tafamidis |
|---|---|
| Baseline (n= 21) | 48.70 ± 44.31 |
| Change at Month 6 (n= 17) | 2.00 ± 9.52 |
| Change at Month 12 (n= 18) | 5.30 ± 12.62 |
NIS-LL: assessed muscle weakness, reflexes and sensation; scored separately for left and right limbs. Components of muscle weakness (hip and knee flexion, hip and knee extension, ankle dorsiflexors, ankle plantar flexors, toe extensors, toe flexors) are scored on 0 to 4 scale, higher score=greater weakness. Components of reflexes (quadriceps femoris, triceps surae) and sensation (touch pressure, pin-prick, vibration, joint position) were scored 0 = normal, 1= decreased, or 2 = absent. Total possible NIS-LL score range 0-88, higher score=greater impairment.
| units on a scale | Tafamidis |
|---|---|
| Baseline (n= 21) | 27.60 ± 24.67 |
| Change at Month 6 (n= 19) | -0.50 ± 5.73 |
| Change at Month 12 (n= 18) | 2.70 ± 6.21 |
Response to treatment was indicated by either improvement (decrease from baseline) or stabilization (change from baseline of 0 to less than \[\<\] 2) in Neuropathy Impairment Score- Lower Limb (NIS-LL) score, based on mean of 2 scores in 1 week period. NIS-LL: assessed muscle weakness, reflexes, sensation. Each item scored separately for left, right limbs. Components of muscle weakness scored on 0(normal) to 4(paralysis) scale, higher score=greater weakness. Components of reflexes, sensation scored 0=normal, 1=decreased, or 2=absent. Total NIS-LL score range 0-88, higher score=greater impairment.
No measurements were reported for this outcome.
TQOL= sum of all Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) items,a 35-item participant-rated questionnaire used to assess impact of diabetic neuropathy on QOL of participants with DN; Item 1 to 7: related to symptoms and presence of symptom was assessed as 1 and absence was assessed as 0. Item 8-35: related to activities of daily living and scored on a 5-point Likert scale, where 0= no problem and 4= severe problem (except item 32, where -2= much better, 0=about the same, 2=much worse). Total TQOL score=-2 to 138;higher score=worse quality of life.
| units on a scale | Tafamidis |
|---|---|
| Baseline (n= 21) | 47.80 ± 35.14 |
| Change at Month 6 (n= 19) | -4.30 ± 13.25 |
| Change at Month 12 (n= 18) | 0.10 ± 18.01 |
Norfolk QOL-DN:35-item participant-rated questionnaire to assess impact of DN on QOL; Item 1-7: scored as 1=symptom present, 0=symptom absent. Item 8-35: scored on 5-point Likert scale:0=no problem, 4=severe problem(except item 32: -2=much better, 0=about same, 2=much worse).Norfolk QOL-DN summarized in 5 domains (score range): physical functioning/large fiber neuropathy(-2 to 58), activities of daily living(ADLs) (0 to 20), symptom(0 to 32), small fiber neuropathy(0 to 16), autonomic neuropathy(0 to 12);higher score=greater impairment, for each. Total score=-2 to 138 (higher score=worse QOL).
| units on a scale | Tafamidis |
|---|---|
| Physical (P)functioning/large fiber:Baseline(n=21) | 25.60 ± 18.50 |
| P functioning/large fiber: Change at Month 6(n=19) | -2.60 ± 8.66 |
| P functioning/large fiber:Change at Month 12(n=18) | -1.40 ± 11.71 |
| ADLs: Baseline (n=21) | 7.30 ± 7.01 |
| ADLs: Change at Month 6 (n=19) | 0.10 ± 3.07 |
| ADLs: Change at Month 12 (n=18) | 0.90 ± 2.58 |
| Symptoms: Baseline (n=21) | 9.00 ± 7.50 |
| Symptoms: Change at Month 6 (n=19) | -0.90 ± 3.05 |
| Symptoms: Change at Month 12 (n=18) | -0.10 ± 4.28 |
| Small fiber neuropathy (SFN): Baseline (n=21) | 3.90 ± 4.92 |
| SFN: Change at Month 6 (n=19) | -0.30 ± 2.54 |
| SFN: Change at Month 12 (n=18) | 0.70 ± 3.22 |
| Autonomic neuropathy (AN): Baseline (n=21)) | 2.00 ± 1.96 |
| AN: Change at Month 6 (n=19) | -0.50 ± 1.61 |
| AN: Change at Month 12 (n=18) | -0.10 ± 1.13 |
NCS: quantitative measures of peripheral nerve dysfunction consists of 5 attributes: peroneal nerve (PN) motor distal latency, PN compound muscle action potential, PN motor conduction velocity, tibial nerve distal motor latency, sural nerve sensory nerve action potential. Normal deviates (Z-score) summated into composite score (higher score=worsened nerve fiber function). Z-score is the defined position of the result in normal probability distribution with a mean of 0 and standard deviation (std) of 1 and describes how far a score is (in std) from the mean.
| Z-score | Tafamidis |
|---|---|
| Baseline (n= 21) | 6.10 ± 5.90 |
| Change at Month 6 (n= 19) | 0.60 ± 2.69 |
| Change at Month 12 (n= 18) | 0.20 ± 3.30 |
HRDB test was used to evaluate the cardio-vagal response. Participant took a series of 8 deep breaths and average heart rate difference was measured and compared to normative data. The main factor affecting HRDB is age, with older patients showing less heart rate variability. R-R (time between two consecutive R waves in the electrocardiogram) response to deep breathing was reported as the normal deviates (Z-score), the defined position of the result in normal probability distribution with a mean of 0 and standard deviation (std) of 1 and describes how far a score is (in std) from the mean.
| Z-score | Tafamidis |
|---|---|
| Baseline (n= 12) | -0.70 ± 2.17 |
| Change at Month 6 (n= 6) | 0.00 ± 2.26 |
| Change at Month 12 (n= 7) | -0.1 ± 1.36 |
BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m\^2). mBMI was calculated by multiplying BMI by serum albumin levels \[gram/liter (g/L)\]. mBMI was measured as kg/m\^2\*g/L. A progressive decline in mBMI indicated worsening of disease severity.
| kg/m^2*g/L | Tafamidis |
|---|---|
| Baseline (n= 20) | 1052.50 ± 206.66 |
| Change at Month 6 (n= 17) | -22.40 ± 77.01 |
| Change at Month 12 (n= 16) | 16.60 ± 89.33 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health and two total scores (physical component summary \[PCS\] and mental component summary \[MCS\]. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
| units on a scale | Tafamidis |
|---|---|
| PCS: Baseline (n= 21) | 36.20 ± 11.90 |
| PCS: Change at Month 6 (n= 18) | 1.60 ± 7.25 |
| PCS: Change at Month 12 (n= 18) | -0.40 ± 8.47 |
| MCS: Baseline (n= 21) | 47.00 ± 10.96 |
| MCS: Change at Month 6 (n= 18) | -1.70 ± 10.02 |
| MCS: Change at Month 12 (n= 18) | 3.00 ± 11.11 |
| Physical functioning: Baseline (n= 21) | 33.20 ± 14.68 |
| Physical functioning: Change at Month 6 (n= 19) | 0.90 ± 7.50 |
| Physical functioning: Change at Month 12 (n= 18) | -0.10 ± 10.84 |
| Role-physical: Baseline (n= 21) | 38.90 ± 13.80 |
| Role-physical: Change at Month 6 (n= 19) | -1.80 ± 10.42 |
| Role-physical: Change at Month 12 (n= 18) | -3.80 ± 12.91 |
| Bodily pain: Baseline (n= 21) | 45.50 ± 11.27 |
| Bodily pain: Change at Month 6 (n= 19) | 0.80 ± 9.42 |
| Bodily pain: Change at Month 12 (n= 18) | 1.50 ± 10.11 |
| General health: Baseline (n= 21) | 36.00 ± 9.47 |
| General health: Change at Month 6 (n= 19) | 2.70 ± 9.97 |
| General health: Change at Month 12 (n= 18) | 4.00 ± 10.33 |
| Vitality: Baseline (n= 21) | 43.30 ± 11.83 |
| Vitality: Change at Month 6 (n= 18) | 1.20 ± 7.95 |
| Vitality: Change at Month 12 (n= 18) | 3.10 ± 9.93 |
| Social functioning: Baseline (n= 21) | 41.80 ± 11.16 |
| Social functioning: Change at Month 6 (n= 19) | 2.00 ± 11.09 |
| Social functioning: Change at Month 12 (n= 18) | 3.00 ± 11.72 |
| Role-emotional: Baseline (n= 21) | 41.60 ± 14.82 |
| Role-emotional: Change at Month 6 (n= 19) | -1.20 ± 7.45 |
| Role-emotional: Change at Month 12 (n= 18) | 0.40 ± 12.43 |
| Mental health: Baseline (n= 21) | 46.90 ± 10.11 |
| Mental health: Change at Month 6 (n= 18) | -3.80 ± 11.47 |
| Mental health: Change at Month 12 (n= 18) | 2.00 ± 12.44 |
Echocardiography was used to measure interventricular septal thickness (IVST), posterior left ventricular wall thickness (PLVWT), right ventricular wall thickness (RVWT), left atrial diameter (LAD): anterior-posterior (ant-post), medio-lateral, superior-inferior (sup-inf) and left ventricular end diastolic diameter (LVED), relative LV wall thickness (RLVWT).
| millimeter (mm) | Tafamidis |
|---|---|
| IVST: Baseline (n=19) | 15.24 ± 2.77 |
| IVST: Change at Month 6 (n=15) | 0.57 ± 2.10 |
| IVST: Change at Month 12 (n=14) | 1.04 ± 2.04 |
| PLVWT: Baseline (n=19) | 14.60 ± 2.59 |
| PLVWT: Change at Month 6 (n=15) | 0.30 ± 1.98 |
| PLVWT: Change at Month 12 (n=14) | 0.70 ± 1.73 |
| RVWT: Baseline (n=17) | 6.09 ± 2.01 |
| RVWT: Change at Month 6 (n=8) | 1.12 ± 1.72 |
| RVWT: Change at Month 12 (n=12) | 1.08 ± 1.29 |
| LAD (ant-post): Baseline (n=21) | 36.30 ± 6.20 |
| LAD (ant-post): Change at Month 6 (n=17) | 1.50 ± 4.57 |
| LAD (ant-post): Change at Month 12 (n=16) | 1.60 ± 3.52 |
| LAD (medio-lateral): Baseline (n=16) | 37.40 ± 4.80 |
| LAD (medio-lateral): Change at Month 6 (n=7) | 4.30 ± 6.90 |
| LAD (medio-lateral): Change at Month 12 (n=9) | 1.90 ± 4.20 |
| LAD (sup-inf): Baseline (n=16) | 48.30 ± 9.88 |
| LAD (sup-inf): Change at Month 6 (n= 8) | 3.10 ± 5.03 |
| LAD (sup-inf): Change at Month 6 (n= 9) | 4.20 ± 6.46 |
| LVED: Baseline (n= 19) | 39.66 ± 4.84 |
| LVED: Change at Month 6 (n= 15) | -1.03 ± 3.88 |
| LVED: Change at Month 12 (n= 14) | 0.11 ± 3.42 |
| RLVWT: Baseline (n=19) | 0.75 ± 0.19 |
| RLVWT: Change at Month 6 (n= 15) | 0.05 ± 0.16 |
| RLVWT: Change at Month 12 (n= 14) | 0.03 ± 0.12 |
Left atrial volume was measured by echocardiography.
| cubic centimeter (cc) | Tafamidis |
|---|---|
| Baseline (n= 15) | 51.50 ± 23.81 |
| Change at Month 6 (n= 6) | 12.30 ± 17.20 |
| Change at Month 12 (n= 9) | 1.90 ± 18.90 |
Cardiac MRI was done to measure left ventricular (LV) end systolic volume, left ventricle (LV) stroke volume.
| milliliter (mL) | Tafamidis |
|---|---|
| LV end systolic volume: Baseline (n= 11) | 30.4 ± 13.93 |
| LV end systolic volume: Change at Month 6 (n= 6) | 3.50 ± 7.79 |
| LV end systolic volume: Change at Month 12 (n= 6) | 4.70 ± 3.01 |
| LV stroke volume: Baseline (n= 11) | 43.10 ± 13.26 |
| LV stroke volume: Change at Month 6 (n= 6) | -2.50 ± 15.23 |
| LV stroke volume: Change at Month 12 (n= 6) | 3.70 ± 10.69 |
Fractional shortening (FS) is the fraction of any diastolic dimension that is lost in systole. Percent of FS was calculated as difference between end-diastolic dimension (EDD) and end-systolic dimension (EDS) divided by EDD.
| percentage of EDD | Tafamidis |
|---|---|
| Baseline (n= 18) | 31.20 ± 5.68 |
| Change at Month 6 (n= 14) | -1.10 ± 5.91 |
| Change at Month 12 (n= 14) | -0.90 ± 6.24 |
Cardiac MRI was done to measure left ventricular ejection fraction (LVEF) which was the fraction of the end-diastolic volume (EDV) that was ejected out of left ventricle with each contraction.
| percentage of EDV | Tafamidis |
|---|---|
| Baseline (n= 21) | 60.30 ± 9.96 |
| Change at Month 6 (n= 18) | -3.80 ± 7.73 |
| Change at Month 12 (n=18) | -2.20 ± 5.37 |
LV mass was calculated from the product of the myocardial volume and specific gravity of heart muscle, estimated by echocardiography. Increased LVM was associated with cardiovascular morbidity and mortality.
| gram | Tafamidis |
|---|---|
| Baseline: (n= 19) | 230.84 ± 62.54 |
| Change at Month 6 (n= 15) | 1.11 ± 46.53 |
| Change at Month 12 (n= 14) | 20.91 ± 35.07 |
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. IVRT is the time between the closure of the aortic valve and the opening of the mitral valve. Mitral deceleration time (MDT) was the time taken from the maximum E point wave to baseline. E wave arises due to early diastolic filling.
| msec | Tafamidis |
|---|---|
| IVRT: Baseline (n= 10) | 84.10 ± 17.51 |
| IVRT: Change at Month 6 (n= 3) | 2.70 ± 20.03 |
| IVRT: Change at Month 12 (n= 8) | -4.00 ± 25.63 |
| MDT: Baseline (n= 18) | 164.00 ± 35.59 |
| MDT: Change at Month 6 (n= 14) | 1.90 ± 28.17 |
| MDT: Change at Month 12 (n= 15) | 11.90 ± 29.45 |
The diameter at the base of the aortic root, the basal ring, is also called the aortic annulus diameter.
| centimeter (cm) | Tafamidis |
|---|---|
| Baseline (n= 21) | 2.045 ± 0.184 |
| Change at Month 6 (n= 17) | -0.009 ± 0.160 |
| Change at Month 12 (n= 16) | -0.041 ± 0.108 |
Tricuspid peak velocity was measured by echocardiography.
| meter per second (m/sec) | Tafamidis |
|---|---|
| Baseline (n= 11) | 26.80 ± 8.62 |
| Change at Month 6 (n= 9) | 0.90 ± 4.86 |
| Change at Month 12 (n= 8) | 2.10 ± 9.25 |
Systolic right ventricular pressure can be estimated on echocardiography by adding right atrial pressure (RAP) to the trans-tricuspid gradient derived from the tricuspid regurgitation velocity.
| millimeter of mercury (mmHg) | Tafamidis |
|---|---|
| Baseline (n= 11) | 35.50 ± 11.55 |
| Change at Month 6 (n= 6) | 3.80 ± 7.81 |
| Change at Month 12 (n= 7) | 2.10 ± 13.08 |
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Doppler principle was used to measure the mitral peak early (E) diastolic transmitral flow, mitral peak atrial (A) contraction velocity and annular velocities at the lateral and septal areas of the mitral annulus. s': systolic velocity during ejection, e': early diastolic mitral annular velocity, a': late diastolic mitral annular velocity.
| centimeter per second (cm/sec) | Tafamidis |
|---|---|
| Mitral Peak A: Baseline (n= 18) | 59.00 ± 23.77 |
| Mitral Peak A: Change at Month 6 (n= 13) | -0.50 ± 16.01 |
| Mitral Peak A: Change at Month 12 (n= 15) | -3.70 ± 15.43 |
| Mitral Peak E: Baseline (n= 19) | 74.10 ± 15.58 |
| Mitral Peak E: Change at Month 6 (n= 15) | 4.70 ± 10.28 |
| Mitral Peak E: Change at Month 12 (n= 16) | 5.10 ± 13.75 |
| Septal s': Baseline (n= 16) | 4.72 ± 1.64 |
| Septal s': Change at Month 6 (n= 12) | 0.43 ± 0.51 |
| Septal s': Change at Month 12 (n= 8) | -0.33 ± 0.90 |
| Septal e': Baseline (n= 16) | 4.54 ± 1.88 |
| Septal e': Change at Month 6 (n= 12) | 1.25 ± 2.29 |
| Septal e': Change at Month 12 (n= 8) | 0.04 ± 0.61 |
| Septal a': Baseline (n= 15) | 4.66 ± 2.67 |
| Septal a': Change at Month 6 (n= 11) | 0.53 ± 1.39 |
| Septal a': Change at Month 12 (n= 8) | -0.10 ± 1.74 |
| Lateral s': Baseline (n= 16) | 6.71 ± 2.97 |
| Lateral s': Change at Month 6 (n= 10) | 0.55 ± 1.41 |
| Lateral s': Change at Month 12 (n= 7) | 0.19 ± 1.20 |
| Lateral e': Baseline (n= 16) | 6.91 ± 2.90 |
| Lateral e': Change at Month 6 (n= 11) | 0.65 ± 1.27 |
| Lateral e': Change at Month 12 (n= 7) | 0.16 ± 1.42 |
| Lateral a': Baseline (n= 15) | 5.93 ± 3.38 |
| Lateral a': Change at Month 6 (n= 10) | 0.31 ± 2.69 |
| Lateral a': Change at Month 12 (n= 6) | -0.45 ± 2.94 |
Doppler echocardiography was a procedure which used ultrasound technology to examine the heart. Ratio of early (E) diastolic transmitral flow velocity and atrial (A) contraction velocity (E/A) and ratio of the early (E) diastolic transmitral flow velocity to the mitral annular velocity (e') (E/e') were estimated.
| ratio | Tafamidis |
|---|---|
| e:e' Lateral: Baseline (n= 16) | 13.148 ± 7.781 |
| e:e' Lateral: Change at Month 6 (n= 10) | -0.145 ± 3.227 |
| e:e' Lateral: Change at Month 12 (n= 7) | -0.243 ± 5.245 |
| E/A: Baseline (n= 18) | 1.463 ± 0.667 |
| E/A: Change at Month 6 (n= 13) | 0.175 ± 0.565 |
| E/A: Change at Month 12 (n= 15) | 0.185 ± 0.658 |
LV mass was calculated from the product of the myocardial volume and specific gravity of heart muscle, estimated by echocardiography. QRS score (the sum of QRS voltages in the peripheral leads) was used as an index of "electrical" LV mass.
| gram/millivolt | Tafamidis |
|---|---|
| Baseline (n= 19) | 5.495 ± 2.149 |
| Change at Month 6 (n= 14) | 0.028 ± 1.479 |
| Change at Month 12 (n= 14) | 0.878 ± 1.437 |
LA volume index (LAVI), was the value of LA volume divided by body surface area, to measure LA size.
| milliliter/square meter (mL/m^2) | Tafamidis |
|---|---|
| Baseline (n= 15) | 27.33 ± 10.21 |
| Change at Month 6 (n= 5) | 7.23 ± 8.78 |
| Change at Month 12 (n= 9) | 1.06 ± 9.66 |
NT-proBNP was a cardiac marker which had the prognostic value for participants with heart failure or left ventricular dysfunction. Higher level of the marker was indicative of heart damage.
| picogram/mL (pg/mL) | Tafamidis |
|---|---|
| Baseline (n= 19) | 1248.89 ± 1529.37 |
| Change at Month 6 (n= 18) | 228.39 ± 834.91 |
| Change at Month 12 (n= 16) | 306.61 ± 1447.67 |
Karnofsky performance score is used to quantify participant's general well-being and activities of daily life and participants are classified based on their functional impairment. Karnofsky performance score is 11 level score which ranges between 0 (death) to 100 (no evidence of disease). Higher score means higher ability to perform daily tasks.
| units on a scale | Tafamidis |
|---|---|
| Baseline (n= 21) | 74.80 ± 14.01 |
| Change at Month 6 (n= 19) | -1.10 ± 5.67 |
| Change at Month 12 (n= 18) | -3.30 ± 5.94 |
Troponin I is a cardiac injury biomarker. Higher concentrations of this marker in blood are associated with heart injury.
| nanogram/mL | Tafamidis |
|---|---|
| Baseline (n= 20) | 0.0234 ± 0.0409 |
| Change at Month 6 (n= 18) | 0.0015 ± 0.0501 |
| Change at Month 12 (n= 18) | 0.0025 ± 0.0487 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tafamidis | — | 8/21 (38.1%) | 13/21 (61.9%) |
| Event | Tafamidis |
|---|---|
| FallInjury, poisoning and procedural complications | 2/21 |
| Atrioventricular blockCardiac disorders | 1/21 |
| Coronary artery stenosisCardiac disorders | 1/21 |
| FaecalomaGastrointestinal disorders | 1/21 |
| SubileusGastrointestinal disorders | 1/21 |
| MalaiseGeneral disorders | 1/21 |
| Ankle fractureInjury, poisoning and procedural complications | 1/21 |
| Avulsion fractureInjury, poisoning and procedural complications | 1/21 |
| ArthritisMusculoskeletal and connective tissue disorders | 1/21 |
| Transient ischaemic attackNervous system disorders | 1/21 |
| Event | Tafamidis |
|---|---|
| DiarrhoeaGastrointestinal disorders | 5/21 |
| FallInjury, poisoning and procedural complications | 4/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 4/21 |
| VomitingGastrointestinal disorders | 3/21 |
| ConstipationGastrointestinal disorders | 3/21 |
| DizzinessNervous system disorders | 3/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/21 |
| NauseaGastrointestinal disorders | 2/21 |
| FatigueGeneral disorders | 2/21 |
| Oedema peripheralGeneral disorders | 2/21 |
| Age Continuous(years) | Tafamidis |
|---|---|
| Mean | 63.10 ± 9.86 |
| Sex: Female, Male(Participants) | Tafamidis |
|---|---|
| Female | 8 |
| Male | 13 |
The record gives a start of Jun 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2012, 2 years 11 months after primary completion. A results delay was requested in Oct 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tafamidis